AARD
Aardvark TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Aardvark retains a differentiated ARD-101 efficacy narrative, meaningful cash runway, and substantial upside if the FDA review establishes a workable safety and development path. The reported median analyst target is $11.75, but the packet provides no target count, limiting its reliability.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +86.7.
What can break
A delayed regulatory resolution could increase cash burn and weaken the stated mid-2027 runway.
Momentum
90
Value
46
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.75 · Bull $12.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.75
Why
Momentum90 · Δ7d +86.7
Value46 · Δ7d 0.0
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendSoftening
Δ7d
+86.7
Δ21d
+86.7
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
52
34% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 89.9 / Value 46.4 / Sentiment 51.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$128.24M
Beta
-
Shares Out
21.88M
P/E (TTM) · Derived
-2.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.07
Rev YoY
-
EPS YoY
+130.5%
Gross Margin
-
Op Margin
-
Net Debt
-$109.59M
Current Ratio
8.06
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology